Art. 8 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

Market exclusivity

In forcesince 26 Jul 2019cited 34×
1.

Where a marketing authorisation in respect of an orphan medicinal product is granted pursuant to Regulation (EEC) No 2309/93 or where all the Member States have granted marketing authorisations in accordance with the procedures for mutual recognition laid down in Articles 7 and 7a of Directive 65/65/EEC or Article 9(4) of Council Directive 75/319/EEC of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products [OJ L 147, 9.6.1975, p. 13. Directive as last amended by Council Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22).], and without prejudice to intellectual property law or any other provision of Community law, the Community and the Member States shall not, for a period of 10 years, accept another application for a marketing authorisation, or grant a marketing authorisation or accept an application to extend an existing marketing authorisation, for the same therapeutic indication, in respect of a similar medicinal product.

2.

This period may however be reduced to six years if, at the end of the fifth year, it is established, in respect of the medicinal product concerned, that the criteria laid down in Article 3 are no longer met, inter alia, where it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. To that end, a Member State shall inform the Agency that the criterion on the basis of which market exclusivity was granted may not be met and the Agency shall then initiate the procedure laid down in Article 5. The sponsor shall provide the Agency with the information necessary for that purpose.

3.

By way of derogation from paragraph 1, and without prejudice to intellectual property law or any other provision of Community law, a marketing authorisation may be granted, for the same therapeutic indication, to a similar medicinal product if:

(a)

the holder of the marketing authorisation for the original orphan medicinal product has given his consent to the second applicant, or

(b)

the holder of the marketing authorisation for the original orphan medicinal product is unable to supply sufficient quantities of the medicinal product, or

(c)

the second applicant can establish in the application that the second medicinal product, although similar to the orphan medicinal product already authorised, is safer, more effective or otherwise clinically superior.

4.

The Commission is empowered to adopt delegated acts in accordance with Article 10b in order to supplement this Regulation by adopting the definitions of ‘similar medicinal product’ and ‘clinical superiority’.

5.

The Commission shall draw up detailed guidelines for the application of this Article in consultation with the Member States, the Agency and interested parties.

The 10 that are cited most themselves, of 34.

  • Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…3Law

    … За целите на прилагането на член 8 от Регламент (ЕО) № 141/2000 за лекарствените продукти-сираци се прилагат следните определения: а) …

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. Now Pharm AG v European Commission.Decision

    Hence, the applicant is wrong in submitting that the Commission should have limited its examination of Ukrain to the matter of whether it offered in itself a clinically relevant advantage or a major contribution to patient care, without …

    9 Sep 2010 · 62008TJ0074

  • Judgment of the General Court (Sixth Chamber), 22 January 2015. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines AgencDecision

    The applicants put forward two pleas in law in support of their action. The first plea alleges infringement of Article 8(1) and (3) of Regulation No 141/2000 in so far as the EMA misinterpreted those provisions by refusing to validate the …

    22 Jan 2015 · 62012TJ0140

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…37Law

    … в член 28, параграф 3 от настоящия регламент, посоченият в член 8, параграф 1 от Регламент (ЕО) № 141/2000 десетгодишен срок се удължава на …

  • Order of the President of the General Court of 1 September 2015 (Extracts). Pari Pharma GmbH v European Medicines Agency.Decision

    В това отношение член 8, параграф 1 от Регламент № 141/2000 предвижда, че лекарствените продукти сираци, за които е издадено РТ се …

    1 Sep 2015 · 62015TO0235(01)

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    … Consequently, Article 8 of Regulation No 141/2000 provides, in essence, that orphan medicinal products in respect of which an MA has been granted enjoy market exclusivity for a period of 10 years, during which no other MA will be issued …

    20 Jul 2016 · 62015TO0718(02)

  • Regulation (EC) No 596/2009 of the European Parliament and of the Council of 18 June 200…Lawamends

  • Regulation (EU) 2019/1243Lawamends

  • Arrêt du Tribunal (septième chambre) du 11 juin 2015. Laboratoires CTRS contre Commission européenne.Decision

    … for the medicinal product Cholic Acid FGK (renamed Kolbam) — Therapeutic indications — Market exclusivity — Article 8(1) of Regulation (EC) No 141/2000) In Case T‑452/14, Laboratoires CTRS, established in Boulogne-Billancourt …

    11 Jun 2015 · 62014TJ0452

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    In the third place, it must be held that potential misuse of the report at issue by a competitor is not in itself a ground for considering that information is commercially confidential under Regulation No 1049/2001. In that regard, it …

    5 Feb 2018 · 62015TJ0718